We searched the Cochrane Library (Jan 1, 2001, to Dec 31, 2015) and Medline (Jan 1, 1970, to Dec 31, 2015) for manuscripts published in English, using the medical subject heading (MeSH) search terms “Asthma” OR “COPD” OR “chronic obstructive airway disease” OR “chronic obstructive pulmonary disease” OR “chronic obstructive lung disease” AND “overlap”. We prioritised publications from the past 5 years. We also searched the reference lists of articles identified by this search strategy and
ReviewThe asthma–COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?
Introduction
In respiratory medicine, the term overlap syndrome has been applied both to the association between obstructive sleep apnoea and chronic obstructive pulmonary disease (COPD)1 and to patients with features of both asthma and COPD (asthma–COPD overlap syndrome [ACOS]).2, 3 In 2014, this syndrome was the topic of a joint publication by the Global Initiative for Asthma (GINA)4 and the Global initiative for Obstructive Lung Disease (GOLD),3, 5 and is beginning to appear in national clinical practice guidelines.6, 7, 8, 9 These developments have been prompted by the following considerations: the recognition that ACOS represents a form of airways disease that is associated with a disproportionate number of exacerbations,10, 11 hospital admissions, and use of health-care resources;12 the fact that patients with ACOS are generally excluded from most trials of new treatments for asthma or COPD; the realisation that asthma and COPD themselves are heterogeneous disorders and that new insights are emerging into the gene–environment interactions involved in different forms of airways diseases and resultant phenotypes; and the emergence of new treatments for asthma and COPD that target specific biological mechanisms of disease (ie, endotypes).13 However, some commentators question whether the description of ACOS as a clinical entity is valid or a useful concept. To address these concerns, this Review discusses the epidemiology, mechanisms of disease, current attempts to define and diagnose ACOS, existing and potential treatment options, and new approaches to the phenotyping and taxonomy of airway diseases.
Section snippets
Epidemiology of ACOS
The reported prevalence of ACOS in different studies varies according to how asthma and COPD were defined, the population sampled (random population samples vs asthma or COPD cohorts), and age group (all adults or older adults [eg, aged >40 years]). When ACOS is defined on the basis of a doctor diagnosis of both asthma and COPD, its prevalence in different cohorts of patients aged 40 years and older with chronic airways disease—including the US NHANES III study,14 the UK GP Research Database,15
Definitions and descriptions of asthma, COPD, and ACOS
When considering how to define ACOS, existing definitions of asthma and COPD would seem the logical place to begin, but they provide little help to the clinician. In 2014, GINA defined asthma as “a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation”.4 The GOLD
Diagnosis of ACOS
Until the past few years,5, 41, 42, 43 clinical practice guidelines have been relatively silent on how to diagnose and manage patients with features of both asthma and COPD (ie, ACOS), except to advise that the two disorders might coexist. Several groups have proposed a more structured approach.31, 44, 45 In 2013, Louie and colleagues44 suggested the diagnosis of ACOS be applied to patients with a doctor diagnosis of both asthma and COPD, a history or evidence of atopy (eg, hayfever or raised
A clinical approach to the diagnosis of chronic airway diseases, including ACOS
In clinical practice, for a clinician to make a diagnosis in patients with chronic airways disease, they need to weigh features of typical asthma or typical COPD that are present against those that are absent. Several of these features call for a quantitative judgment; for example, what level of smoking history (number of pack-years) would change the diagnosis from asthma to COPD if all other features favoured asthma? In the global context, how much exposure to biomass or other risk factors
Approach to treatment in ACOS
Although overlapping or mixed asthma and COPD are described in some recent national COPD guidelines6, 7, 9 and the GINA4 and GOLD5 strategy documents, almost no high quality data exist on which to base treatment recommendations, because patients with ACOS have been specifically excluded from trials investigating treatments for asthma or COPD. However, many clinicians have experience of empirical treatment of such patients with drugs approved for asthma or COPD. At present, the GINA–GOLD document
Need for a new taxonomy of airways diseases based on progress in endotyping and phenotyping
The argument for a new taxonomy for chronic airways diseases is compelling.61, 62 The creation of a new taxonomy is not an academic exercise, but is essential for an improved understanding of the natural histories and pathogenesis of these disorders, and as part of the personalised (precision) medicine approach to find treatments for unmet needs, particularly for severe forms of disease.59, 63, 64
The existing classification of airways disease into asthma and COPD involves a-priori assumptions
Pathways to ACOS and the Dutch hypothesis of chronic airways disease
ACOS is generally only used as a potential diagnosis in adults aged 40 years and older (midway through life). Detailed studies comparing elderly patients with chronic asthma and fixed airflow limitation with age-matched patients with COPD, confirm differences in airway morphology and inflammation, implying that lifelong asthma does not morph into the usual forms of COPD, but ageing inevitably plays a part in chronic airflow limitation.76, 77 The origins of airway diseases in adulthood can be
Conclusions and future research
The understanding of chronic airways disease in adults with features both of asthma and COPD (so-called ACOS) is incomplete, and its treatment omitted from previous regulatory studies and treatment guidelines. Existing descriptions of ACOS are intended, in the first instance, as interim advice to assist clinical management of airways disease by non-specialist physicians, not as definitive statement. Preliminary advice in most publications is to treat patients with suspected ACOS with both a
Search strategy and selection criteria
References (88)
- et al.
Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities
J Proteomics
(2011) - et al.
The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom
Chest
(2003) Coexisting asthma and COPD: confused clinicians or poor prognosticator?
Chest
(2008)- et al.
Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study
Chest
(2007) - et al.
The course of persistent airflow limitation in subjects with and without asthma
Respir Med
(2008) - et al.
Do symptoms predict COPD in smokers?
Chest
(2010) - et al.
Patterns of comorbidities in newly diagnosed COPD and asthma in primary care
Chest
(2005) - et al.
Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke
Arch Bronconeumol
(2014) - et al.
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management
Lancet
(2015) - et al.
Consensus document on the overlap phenotype COPD-asthma in COPD
Arch Bronconeumol
(2012)
Clinical phenotypes of COPD: identification, definition and implications for guidelines
Arch Bronconeumol
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Lancet
Why doesn't reducing exacerbations decrease COPD mortality?
Lancet Respir Med
New treatments for severe treatment-resistant asthma: targeting the right patient
Lancet Respir Med
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial
Lancet
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Lancet
Efficacy and safety of roflumilast in the treatment of asthma
Ann Allergy Asthma Immunol
Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials
Lancet Respir Med
Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease
Respir Res
Integrating the overlap of obstructive lung disease and obstructive sleep apnoea: OLDOSA syndrome
Respirology
The asthma-COPD overlap syndrome: a common clinical problem in the elderly
J Allergy (Cairo)
Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS)
Global strategy for asthma management and prevention
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease
A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)
Prim Care Respir J
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update
Can Respir J
[Guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 3rd edition]
Nihon Rinsho
Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines
Basic Clin Pharmacol Toxicol
The clinical features of the overlap between COPD and asthma
Respir Res
The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population
PloS One
High hospital burden in overlap syndrome of asthma and COPD
Clin Respir J
Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994
Arch Intern Med
Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment
COPD
Overlap syndrome of asthma and COPD predicts low quality of life
J Asthma
Factors associated with persistent airflow limitation in severe asthma
Am J Respir Crit Care Med
Childhood asthma and GOLD-defined chronic obstructive pulmonary disease
Intern Med J
Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up
Thorax
Interpretative strategies for lung function tests
Eur Respir J
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease
Thorax
Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
Respir Res
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team
Am J Respir Crit Care Med
Proportional classifications of COPD phenotypes
Thorax
Early life origins of chronic obstructive pulmonary disease
Thorax
A longitudinal, population-based, cohort study of childhood asthma followed to adulthood
N Engl J Med
Cited by (140)
Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
2023, Journal of Allergy and Clinical Immunology: In PracticeThere is still no established and accepted definition of COPD
2023, Respiratory MedicineAsthma and COPD: distinct diseases or components of a continuum?
2023, Asthma in the 21st Century: New Research AdvancesUnmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap
2022, Immunology and Allergy Clinics of North AmericaWalking the path of treatable traits in interstitial lung diseases
2023, Respiratory Research